PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects

Tyler J. Fraum; Daniel R. Ludwig; Thomas A. Hope; Kathryn J. Fowler

doi:10.1016/j.gtc.2018.04.011

PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects

Tyler J. Fraum, Daniel R. Ludwig, Thomas A. Hope, Kathryn J. Fowler

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

Positron emission tomography (PET)/computed tomography (CT) with 2-deoxy-2-[¹⁸F]fluoro-D-glucose (FDG) has become the standard of care for the initial staging and subsequent treatment response assessment for numerous gastrointestinal malignancies. However, it is often supplemented by magnetic resonance imaging (MRI) for local tumor staging. Hybrid PET/MRI scanners, which acquire PET data and MRI data simultaneously, have the potential to provide accurate whole-body staging in a single examination. Furthermore, to address certain limitations of FDG, many new PET tracers have been developed to probe distinctive aspects of tumor biology.

Original language	English
Pages (from-to)	691-714
Number of pages	24
Journal	Gastroenterology Clinics of North America
Volume	47
Issue number	3
DOIs	https://doi.org/10.1016/j.gtc.2018.04.011
State	Published - Sep 2018

Keywords

Colorectal cancer
Hepatocellular carcinoma
Neuroendocrine tumor
PET/MRI
Pancreatic cancer

Access to Document

10.1016/j.gtc.2018.04.011

Cite this

@article{ea5fe1c50e49449286880039aa9eea66,

title = "PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects",

abstract = "Positron emission tomography (PET)/computed tomography (CT) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has become the standard of care for the initial staging and subsequent treatment response assessment for numerous gastrointestinal malignancies. However, it is often supplemented by magnetic resonance imaging (MRI) for local tumor staging. Hybrid PET/MRI scanners, which acquire PET data and MRI data simultaneously, have the potential to provide accurate whole-body staging in a single examination. Furthermore, to address certain limitations of FDG, many new PET tracers have been developed to probe distinctive aspects of tumor biology.",

keywords = "Colorectal cancer, Hepatocellular carcinoma, Neuroendocrine tumor, PET/MRI, Pancreatic cancer",

author = "Fraum, {Tyler J.} and Ludwig, {Daniel R.} and Hope, {Thomas A.} and Fowler, {Kathryn J.}",

note = "Funding Information: Disclosures: T.A. Hope receives grant support from GE Healthcare . The other authors have nothing to disclose. Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = sep,

doi = "10.1016/j.gtc.2018.04.011",

language = "English",

volume = "47",

pages = "691--714",

journal = "Gastroenterology Clinics of North America",

issn = "0889-8553",

number = "3",

}

TY - JOUR

T1 - PET/MRI for Gastrointestinal Imaging

T2 - Current Clinical Status and Future Prospects

AU - Fraum, Tyler J.

AU - Ludwig, Daniel R.

AU - Hope, Thomas A.

AU - Fowler, Kathryn J.

PY - 2018/9

Y1 - 2018/9

N2 - Positron emission tomography (PET)/computed tomography (CT) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has become the standard of care for the initial staging and subsequent treatment response assessment for numerous gastrointestinal malignancies. However, it is often supplemented by magnetic resonance imaging (MRI) for local tumor staging. Hybrid PET/MRI scanners, which acquire PET data and MRI data simultaneously, have the potential to provide accurate whole-body staging in a single examination. Furthermore, to address certain limitations of FDG, many new PET tracers have been developed to probe distinctive aspects of tumor biology.

AB - Positron emission tomography (PET)/computed tomography (CT) with 2-deoxy-2-[18F]fluoro-D-glucose (FDG) has become the standard of care for the initial staging and subsequent treatment response assessment for numerous gastrointestinal malignancies. However, it is often supplemented by magnetic resonance imaging (MRI) for local tumor staging. Hybrid PET/MRI scanners, which acquire PET data and MRI data simultaneously, have the potential to provide accurate whole-body staging in a single examination. Furthermore, to address certain limitations of FDG, many new PET tracers have been developed to probe distinctive aspects of tumor biology.

KW - Colorectal cancer

KW - Hepatocellular carcinoma

KW - Neuroendocrine tumor

KW - PET/MRI

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=85049452647&partnerID=8YFLogxK

U2 - 10.1016/j.gtc.2018.04.011

DO - 10.1016/j.gtc.2018.04.011

M3 - Review article

C2 - 30115444

AN - SCOPUS:85049452647

VL - 47

SP - 691

EP - 714

JO - Gastroenterology Clinics of North America

JF - Gastroenterology Clinics of North America

SN - 0889-8553

IS - 3

ER -

PET/MRI for Gastrointestinal Imaging: Current Clinical Status and Future Prospects

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this